|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan A, Yeh SH, Liu CJ, Cheung C and Chen
PJ: Viral hepatocarcinogenesis: from infection to cancer. Liver
Int. 28:175–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rana TM: Illuminating the silence:
Understanding the structure and function of small RNAs. Nat Rev Mol
Cell Biol. 8:23–36. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: How many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berezikov E, Guryev V, van de Belt J,
Wienholds E, Plasterk RH and Cuppen E: Phylogenetic shadowing and
computational identification of human microRNA genes. Cell.
120:21–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang J, Gusev Y, Aderca I, Mettler TA,
Nagorney DM, Brackett DJ, Roberts LR and Schmittgen TD: Association
of MicroRNA expression in hepatocellular carcinomas with hepatitis
infection, cirrhosis, and patient survival. Clin Cancer Res.
14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang WY, Zhang HF, Wang L, Ma YP, Gao F,
Zhang SJ and Wang LC: miR-21 expression predicts prognosis in
hepatocellular carcinoma. Clin Res Hepatol Gastroenterol.
38:715–719. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et
al: MicroRNAs regulate critical genes associated with multiple
myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia H, Zhang W, Zhang B, Zhao Y, Zhao Y,
Li S and Liu Y: miR-21 modulates the effect of EZH2 on the
biological behavior of human lung cancer stem cells in vitro.
Oncotarget. 8:85442–85451. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L
and Huang Y: miR-21 promotes migration and invasion by the
miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.
Oncol Rep. 27:1660–1668. 2012.PubMed/NCBI
|
|
17
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frankel LB, Christoffersen NR, Jacobsen A,
Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is
an important functional target of the microRNA miR-21 in breast
cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Zhu Z, Watabe K, Zhang X, Bai C,
Xu M, Wu F and Mo YY: Negative regulation of lncRNA GAS5 by miR-21.
Cell Death Differ. 20:1558–1568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao
Y, Li Y, Zeng T, Hu J, Zhang L, et al: HBx-mediated miR-21
upregulation represses tumor-suppressor function of PDCD4 in
hepatocellular carcinoma. Oncogene. 32:3296–3305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sicard F, Gayral M, Lulka H, Buscail L and
Cordelier P: Targeting miR-21 for the therapy of pancreatic cancer.
Mol Ther. 21:986–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen C, Bhalala HV, Qiao H and Dong JT: A
possible tumor suppressor role of the KLF5 transcription factor in
human breast cancer. Oncogene. 21:6567–6572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao Y, Wu K, Chen Y, Zhou J, Du C, Shi Q,
Xu S, Jia J, Tang X, Li F, et al: Beyond proliferation: KLF5
promotes angiogenesis of bladder cancer through directly regulating
VEGFA transcription. Oncotarget. 6:43791–43805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen C, Bhalala HV, Vessella RL and Dong
JT: KLF5 is frequently deleted and down-regulated but rarely
mutated in prostate cancer. Prostate. 55:81–88. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wagenaar TR, Zabludoff S, Ahn SM, Allerson
C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, et
al: Anti-miR-21 suppresses hepatocellular carcinoma growth via
broad transcriptional network deregulation. Mol Cancer Res.
13:1009–1021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sazanov AA, Kiselyova EV, Zakharenko AA,
Romanov MN and Zaraysky MI: Plasma and saliva miR-21 expression in
colorectal cancer patients. J Appl Genet. 58:231–237. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lasithiotaki I, Tsitoura E, Koutsopoulos
A, Lagoudaki E, Koutoulaki C, Pitsidianakis G, Spandidos DA,
Siafakas NM, Sourvinos G and Antoniou KM: Aberrant expression of
miR-21, miR-376c and miR-145 and their target host genes in Merkel
cell polyomavirus-positive non-small cell lung cancer. Oncotarget.
8:112371–112383. 2016.PubMed/NCBI
|
|
31
|
Charkiewicz R, Pilz L, Sulewska A,
Kozlowski M, Niklinska W, Moniuszko M, Reszec J, Manegold C and
Niklinski J: Validation for histology-driven diagnosis in non-small
cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two
different normalization strategies. Int J Cancer. 138:689–697.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu Y, Nangia-Makker P, Farhana L, G
Rajendra S, Levi E and Majumdar AP: miR-21 and miR-145 cooperation
in regulation of colon cancer stem cells. Mol Cancer. 14:982015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li ZB, Li ZZ, Li L, Chu HT and Jia M:
MiR-21 and miR-183 can simultaneously target SOCS6 and modulate
growth and invasion of hepatocellular carcinoma (HCC) cells. Eur
Rev Med Pharmacol Sci. 19:3208–3217. 2015.PubMed/NCBI
|
|
34
|
Adam O, Löhfelm B, Thum T, Gupta SK, Puhl
SL, Schäfers HJ, Böhm M and Laufs U: Role of miR-21 in the
pathogenesis of atrial fibrosis. Basic Res Cardiol. 107:2782012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tetreault MP, Yang Y and Katz JP:
Krüppel-like factors in cancer. Nat Rev Cancer. 13:701–713. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong JT and Chen C: Essential role of KLF5
transcription factor in cell proliferation and differentiation and
its implications for human diseases. Cell Mol Life Sci.
66:2691–2706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen
W, Chen H, Dong C, Yang R, Liu S, et al: Mifepristone suppresses
basal triple-negative breast cancer stem cells by down-regulating
KLF5 expression. Theranostics. 6:533–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakajima Y, Osakabe A, Waku T, Suzuki T,
Akaogi K, Fujimura T, Homma Y, Inoue S and Yanagisawa J: Estrogen
exhibits a biphasic effect on prostate tumor growth through the
estrogen receptor β-KLF5 pathway. Mol Cell Biol. 36:144–156.
2015.PubMed/NCBI
|
